Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates

The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had take...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Osteoporosis international 2017-03, Vol.28 (3), p.1145-1147
Hauptverfasser: Sánchez, A., Blanco, R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1147
container_issue 3
container_start_page 1145
container_title Osteoporosis international
container_volume 28
creator Sánchez, A.
Blanco, R.
description The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of −2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.
doi_str_mv 10.1007/s00198-016-3840-z
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1842548453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2008064243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-1c625835470ef0a12a70865cceaa2e9e39348c824f9c64a855de039881a8fc613</originalsourceid><addsrcrecordid>eNp1kU9rFDEYh4Modlv9AF4k4GV7GJt_k0mOpbjWUtxLBW8hzb7jZplNxiRD2X4AP7cZtioUPIQXkuf3S8iD0DtKPlJCuotMCNWqIVQ2XAnSPL5ACyo4b5iW7Uu0IJp3jRb0-wk6zXlHakbr7jU6YZ2SktFugX6tc4EYwKWYfcaxx2ULeGcf8HL99eYc27DBthxG7-yAe9jHNM9kXZkS4OXlanWOfagYjnPRGFMs3uHRFg-hYLdNMczZ4YBLAltggx982eJ7n8dtnFeom_kNetXbIcPbp3mGvq0-3V1dN7frz1-uLm8bx7UqDXWStYq3oiPQE0uZ7YiSrXNgLQMNXHOhnGKi104Kq9p2A6QmFbWqd5LyM7Q89o4p_pwgF7P32cEw2ABxyoYqwVqhRMsr-uEZuotTCvV1hhGiiBRMzBQ9UvMH5gS9GZPf23QwlJhZkjlKMlWSmSWZx5p5_9Q83e9h8zfxx0oF2BHI9Sj8gPTv6v-3_gbmO53D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2008064243</pqid></control><display><type>article</type><title>Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Sánchez, A. ; Blanco, R.</creator><creatorcontrib>Sánchez, A. ; Blanco, R.</creatorcontrib><description>The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of −2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-016-3840-z</identifier><identifier>PMID: 27866217</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Aged, 80 and over ; Alendronate - administration &amp; dosage ; Alendronate - adverse effects ; Alendronic acid ; Analgesics ; Antibiotics ; Back pain ; Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging ; Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology ; Bisphosphonates ; Bone Density Conservation Agents - administration &amp; dosage ; Bone Density Conservation Agents - adverse effects ; Calcitonin ; Calcitriol ; Calcium (blood) ; Calcium phosphates ; Cancer ; Case Report ; Collagen ; Densitometry ; Diphosphonates - administration &amp; dosage ; Diphosphonates - adverse effects ; Drug Administration Schedule ; Drug Therapy, Combination ; Dual energy X-ray absorptiometry ; Endocrinology ; Female ; Femur ; Fractures ; Fractures, Spontaneous - chemically induced ; Fractures, Spontaneous - diagnostic imaging ; Geriatrics ; Hip ; Hip Fractures - chemically induced ; Hip Fractures - diagnostic imaging ; Humans ; Imidazoles - administration &amp; dosage ; Imidazoles - adverse effects ; Jaw ; Low back pain ; Magnetic resonance imaging ; Mandible ; Medicine ; Medicine &amp; Public Health ; Monoclonal antibodies ; Orthopedics ; Osteonecrosis ; Osteoporosis ; Osteoporosis, Postmenopausal - drug therapy ; Pain ; Parathyroid hormone ; Radiography ; Rheumatology ; Targeted cancer therapy ; Teeth ; Zoledronic acid</subject><ispartof>Osteoporosis international, 2017-03, Vol.28 (3), p.1145-1147</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2016</rights><rights>Osteoporosis International is a copyright of Springer, (2016). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-1c625835470ef0a12a70865cceaa2e9e39348c824f9c64a855de039881a8fc613</citedby><cites>FETCH-LOGICAL-c398t-1c625835470ef0a12a70865cceaa2e9e39348c824f9c64a855de039881a8fc613</cites><orcidid>0000-0002-0761-4385</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-016-3840-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-016-3840-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27866217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sánchez, A.</creatorcontrib><creatorcontrib>Blanco, R.</creatorcontrib><title>Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of −2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.</description><subject>Aged, 80 and over</subject><subject>Alendronate - administration &amp; dosage</subject><subject>Alendronate - adverse effects</subject><subject>Alendronic acid</subject><subject>Analgesics</subject><subject>Antibiotics</subject><subject>Back pain</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology</subject><subject>Bisphosphonates</subject><subject>Bone Density Conservation Agents - administration &amp; dosage</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Calcitonin</subject><subject>Calcitriol</subject><subject>Calcium (blood)</subject><subject>Calcium phosphates</subject><subject>Cancer</subject><subject>Case Report</subject><subject>Collagen</subject><subject>Densitometry</subject><subject>Diphosphonates - administration &amp; dosage</subject><subject>Diphosphonates - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Dual energy X-ray absorptiometry</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Femur</subject><subject>Fractures</subject><subject>Fractures, Spontaneous - chemically induced</subject><subject>Fractures, Spontaneous - diagnostic imaging</subject><subject>Geriatrics</subject><subject>Hip</subject><subject>Hip Fractures - chemically induced</subject><subject>Hip Fractures - diagnostic imaging</subject><subject>Humans</subject><subject>Imidazoles - administration &amp; dosage</subject><subject>Imidazoles - adverse effects</subject><subject>Jaw</subject><subject>Low back pain</subject><subject>Magnetic resonance imaging</subject><subject>Mandible</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Monoclonal antibodies</subject><subject>Orthopedics</subject><subject>Osteonecrosis</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Pain</subject><subject>Parathyroid hormone</subject><subject>Radiography</subject><subject>Rheumatology</subject><subject>Targeted cancer therapy</subject><subject>Teeth</subject><subject>Zoledronic acid</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9rFDEYh4Modlv9AF4k4GV7GJt_k0mOpbjWUtxLBW8hzb7jZplNxiRD2X4AP7cZtioUPIQXkuf3S8iD0DtKPlJCuotMCNWqIVQ2XAnSPL5ACyo4b5iW7Uu0IJp3jRb0-wk6zXlHakbr7jU6YZ2SktFugX6tc4EYwKWYfcaxx2ULeGcf8HL99eYc27DBthxG7-yAe9jHNM9kXZkS4OXlanWOfagYjnPRGFMs3uHRFg-hYLdNMczZ4YBLAltggx982eJ7n8dtnFeom_kNetXbIcPbp3mGvq0-3V1dN7frz1-uLm8bx7UqDXWStYq3oiPQE0uZ7YiSrXNgLQMNXHOhnGKi104Kq9p2A6QmFbWqd5LyM7Q89o4p_pwgF7P32cEw2ABxyoYqwVqhRMsr-uEZuotTCvV1hhGiiBRMzBQ9UvMH5gS9GZPf23QwlJhZkjlKMlWSmSWZx5p5_9Q83e9h8zfxx0oF2BHI9Sj8gPTv6v-3_gbmO53D</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Sánchez, A.</creator><creator>Blanco, R.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0761-4385</orcidid></search><sort><creationdate>20170301</creationdate><title>Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates</title><author>Sánchez, A. ; Blanco, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-1c625835470ef0a12a70865cceaa2e9e39348c824f9c64a855de039881a8fc613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged, 80 and over</topic><topic>Alendronate - administration &amp; dosage</topic><topic>Alendronate - adverse effects</topic><topic>Alendronic acid</topic><topic>Analgesics</topic><topic>Antibiotics</topic><topic>Back pain</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology</topic><topic>Bisphosphonates</topic><topic>Bone Density Conservation Agents - administration &amp; dosage</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Calcitonin</topic><topic>Calcitriol</topic><topic>Calcium (blood)</topic><topic>Calcium phosphates</topic><topic>Cancer</topic><topic>Case Report</topic><topic>Collagen</topic><topic>Densitometry</topic><topic>Diphosphonates - administration &amp; dosage</topic><topic>Diphosphonates - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Dual energy X-ray absorptiometry</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Femur</topic><topic>Fractures</topic><topic>Fractures, Spontaneous - chemically induced</topic><topic>Fractures, Spontaneous - diagnostic imaging</topic><topic>Geriatrics</topic><topic>Hip</topic><topic>Hip Fractures - chemically induced</topic><topic>Hip Fractures - diagnostic imaging</topic><topic>Humans</topic><topic>Imidazoles - administration &amp; dosage</topic><topic>Imidazoles - adverse effects</topic><topic>Jaw</topic><topic>Low back pain</topic><topic>Magnetic resonance imaging</topic><topic>Mandible</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Monoclonal antibodies</topic><topic>Orthopedics</topic><topic>Osteonecrosis</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Pain</topic><topic>Parathyroid hormone</topic><topic>Radiography</topic><topic>Rheumatology</topic><topic>Targeted cancer therapy</topic><topic>Teeth</topic><topic>Zoledronic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez, A.</creatorcontrib><creatorcontrib>Blanco, R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez, A.</au><au>Blanco, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>28</volume><issue>3</issue><spage>1145</spage><epage>1147</epage><pages>1145-1147</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of −2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.</abstract><cop>London</cop><pub>Springer London</pub><pmid>27866217</pmid><doi>10.1007/s00198-016-3840-z</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-0761-4385</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0937-941X
ispartof Osteoporosis international, 2017-03, Vol.28 (3), p.1145-1147
issn 0937-941X
1433-2965
language eng
recordid cdi_proquest_miscellaneous_1842548453
source MEDLINE; SpringerLink Journals
subjects Aged, 80 and over
Alendronate - administration & dosage
Alendronate - adverse effects
Alendronic acid
Analgesics
Antibiotics
Back pain
Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging
Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology
Bisphosphonates
Bone Density Conservation Agents - administration & dosage
Bone Density Conservation Agents - adverse effects
Calcitonin
Calcitriol
Calcium (blood)
Calcium phosphates
Cancer
Case Report
Collagen
Densitometry
Diphosphonates - administration & dosage
Diphosphonates - adverse effects
Drug Administration Schedule
Drug Therapy, Combination
Dual energy X-ray absorptiometry
Endocrinology
Female
Femur
Fractures
Fractures, Spontaneous - chemically induced
Fractures, Spontaneous - diagnostic imaging
Geriatrics
Hip
Hip Fractures - chemically induced
Hip Fractures - diagnostic imaging
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Jaw
Low back pain
Magnetic resonance imaging
Mandible
Medicine
Medicine & Public Health
Monoclonal antibodies
Orthopedics
Osteonecrosis
Osteoporosis
Osteoporosis, Postmenopausal - drug therapy
Pain
Parathyroid hormone
Radiography
Rheumatology
Targeted cancer therapy
Teeth
Zoledronic acid
title Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A59%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteonecrosis%20of%20the%20jaw%20(ONJ)%20and%20atypical%20femoral%20fracture%20(AFF)%20in%20an%20osteoporotic%20patient%20chronically%20treated%20with%20bisphosphonates&rft.jtitle=Osteoporosis%20international&rft.au=S%C3%A1nchez,%20A.&rft.date=2017-03-01&rft.volume=28&rft.issue=3&rft.spage=1145&rft.epage=1147&rft.pages=1145-1147&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-016-3840-z&rft_dat=%3Cproquest_cross%3E2008064243%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2008064243&rft_id=info:pmid/27866217&rfr_iscdi=true